



Holista CollTech Limited

(ASX:HCT / ABN 24 094 515 992)

283 Rokeby Road Subiaco WA 6008

P: +61 8 6141 3500 ; F: +61 8 6141 3599 W: www.holistaco.com

ASX Announcement

14 August 2019

ANNOUNCEMENT BY SINGAPORE eDEVELOPMENT LIMITED

ASX-listed Holista CollTech Limited (ASX:HCT, **Holista**) is pleased to share the following announcement by SINGAPORE eDEVELOPMENT LIMITED's (**SeD**) – the United States based subsidiary - Global BioLife Inc. The Company owns a 10% stake in Global BioLife Inc. The announcement was released to the Singapore Exchange Limited.

The product which is a low Glycaemic Index (**low GI**) sugar mentioned in the release is not in competition or conflict with the low GI sugar technology produced by HCT. In fact, it enhances the position of HCT in the low GI space.

The director of Holista, Chan Heng Fai, is the Chairman of SeD and its largest shareholder.

Please refer to the attached announcement.

Brett Fraser

Joint Company Secretary

For further information, please contact:

Corporate Affairs & Business Opportunities

Dr Rajen Manicka: rajen.m@holistaco.com

General Enquiries: enquiries@holistaco.com

Australia

283 Rokeby Road

Subiaco WA 6008

P: +61 8 6141 3500 ; F: +61 8 6141 3599

Malaysia

12th Floor, Amcorp Trade Centre, PJ Tower

No. 18, Persiaran Barat off Jalan Timur

46000, Petaling Jaya, Malaysia

P: +603 7965 2828 ; F: +603 7965 2777

Media and Investor Relations Enquiries

WeR1 Consultants Pte Ltd

3 Phillip Street #12-01

Singapore 048693

holista@wer1.net; P: +65 67374844

Singapore eDevelopment Limited

(Company Registration Number 200916763W)
7 Temasek Boulevard, #29-01B Suntec Tower One,
Singapore 038987

Global BioLife Inc.’s Naturally Modified Sugar, Laetose™, Unveiled at Harvard Health Summit

SINGAPORE, 23 July 2019 – Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) (“**SeD**”) is pleased to announce the results of clinical trials conducted on Laetose™, developed by its U.S. biomedical subsidiary, Global BioLife Inc. (“**Global BioLife**”).

Clinical trial results show that Laetose™ is a new sugar product that reduces its negative impact on the body. It is a healthier sweetener that is identical to regular sugar in taste, texture and shelf life. As a result of this medical advancement in the fight against diabetes and obesity, Global BioLife’s Director of Scientific Initiatives, Mr Daryl L. Thompson (“Mr Thompson”), was recently invited to present to health ambassadors from around the world at Harvard Medical School’s Global Health Catalyst Summit, an annual event that focuses on initiatives to eliminate global health disparities.

Laetose™ was developed by Mr Thompson, as a safer affordable alternative to sugar. This naturally modified table sugar from Global BioLife carries 30% fewer calories and a glycemic index score of 53 to a score of 100 in glucose.

“You can think of Laetose™ as Sugar 2.0. It is simply more than a low-calorie sugar but rather a solution to sugar itself in that it was specifically formulated to fight disease,” said Mr Thompson. *“We’ve developed a formula that uses sugar the way nature intended. Laetose™ tastes and performs exactly like sugar as a food ingredient but it is better accepted by the body.”*

At the Global Health Catalyst Summit, Mr Thompson announced the completion of human trials on Laetose™ conducted at one of the foremost laboratories in the world to measure glycemic index. Additional independent testing conducted at Charles River Laboratories shows Laetose™ halts stimulation of lipopolysaccharide inflammation which leads to Metabolic Endotoxemia, the root of metabolic-driven disease.

Global BioLife has partnered with Quality Candy Company LLC to form a joint venture, Sweet Sense Inc. ("**Sweet Sense**"), to produce and market Laetose™. Sweet Sense refined the invention at its production facility and created a scalable manufacturing process for Laetose™.

"Clinical trials are complete, patents have been filed and the product is ready for full-scale production," said Mr Thompson. Sweet Sense is looking to licence Laetose™ and is sourcing for companies with the ability to introduce Laetose™ into multiple food products around the world.

Shareholders and potential investors of SeD are advised to exercise caution when dealing or trading in the securities of SeD. In particular, shareholders and potential investors of SeD should note that there is no certainty or assurance that Laetose™ will be licensed or close to monetisation. Shareholders and potential investors of SeD are advised to read this Media Release and any further announcements made by SeD carefully. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

End of Media Release

About Singapore eDevelopment Limited

Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities.

For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.

About Global BioLife Inc.

Global BioLife Inc. (“GBLI”) is a 70%-held direct subsidiary of Global BioMedical Inc., which is a wholly-owned direct subsidiary of Singapore BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. The remaining shareholding of Global BioLife Inc. is held by Global Research and Discovery Group Scientific LLC (“GRDGS”) at 20% and Australian Exchange-listed Holista CollTech Limited (“Holista”) at 10%.

With an aging population and a growing focus in healthcare issues, biomedical science has become increasingly vital. GBLI strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDGS and Holista, GBLI pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition and treatment of neurological, oncology and immuno-related diseases. GBLI is also collaborating with its partners to develop second generation mosquito defense technologies, which are DEET alternatives, to protect against mosquito transmitted diseases such as Zika, Dengue, West Nile Virus and Malaria.

For more information, please visit: <http://www.globalbiolife.com>

This Media Release has been reviewed by the Company's Sponsor, Hong Leong Finance Limited. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this Media Release, including the correctness of any of the statements or opinions made or reports contained in this Media Release

The contact person for the Sponsor is Mr Tang Yeng Yuen, Vice President, Head of Corporate Finance, Hong Leong Finance Limited, at 16 Raffles Quay, #01-05 Hong Leong Building, Singapore 048581, telephone (+65) 6415 9886.